Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NBTY appoints new CEO
Most recently, Nagel worked as the head of General Electric Company (GE) Oil & Gas Global Services and was based in Florence, Italy. Nagel held senior leadership positions
Most recently, Nagel worked as the head of General Electric Company (GE) Oil & Gas Global Services and was based in Florence, Italy. Nagel held senior leadership positions
unithink said that Cline comes to the company after successful stints at National Clinical Research and etrials, where he was a founder and CEO. While at etrials, Cline
Under the collaboration agreement, Invida will be Sinclair’s exclusive partner in eleven markets within the Asia Pacific region for its dermatology and wound care brands in what is
Marck Biosciences intends to increase its manufacturing capacity for large volume injectibles by over 33% by March 2011, The Business Standard reported. The company plans to manufacture large
CareFusion will provide the VA with a suite of positive patient identification products to help reduce the potential for errors during blood transfusion and specimen collection. The Pyxis
Research suggests that the subtype classification and prognostic score generated by the PAM50 gene signature provides information about the fundamental biology of breast cancer that cannot be gained
Belimumab is an investigational drug and the first in a new class of drugs called BLyS-specific inhibitors. After the FDA Arthritis Advisory Committee met on November 16, 2010
APL 130277 is a reformulation of the currently marketed injection into an oral formulation that will follow an expedited clinical development path of 18-24 months based on the
Pfizer has begun the process of preparing a marketing authorization application (MAA) for submission to the European Medicine Agency (EMA) for Bosutinib as a treatment option for patients
Rituxan/MabThera is a therapeutic antibody that binds to a particular protein – the CD20 antigen – on the surface of normal and malignant B-cells. It then recruits the